

Anil K Chaturvedi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8472302/publications.pdf>

Version: 2024-02-01

110
papers

18,146
citations

34100

52
h-index

28296

105
g-index

111
all docs

111
docs citations

111
times ranked

18785
citing authors

#	ARTICLE	IF	CITATIONS
1	Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States. <i>Journal of Clinical Oncology</i> , 2011, 29, 4294-4301.	1.6	3,060
2	Incidence Trends for Human Papillomavirus-Related and -Unrelated Oral Squamous Cell Carcinomas in the United States. <i>Journal of Clinical Oncology</i> , 2008, 26, 612-619.	1.6	1,366
3	Worldwide Trends in Incidence Rates for Oral Cavity and Oropharyngeal Cancers. <i>Journal of Clinical Oncology</i> , 2013, 31, 4550-4559.	1.6	1,046
4	Prevalence of Oral HPV Infection in the United States, 2009-2010. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 693.	7.4	875
5	Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3235-3242.	1.6	873
6	Selection Criteria for Lung-Cancer Screening. <i>New England Journal of Medicine</i> , 2013, 368, 728-736.	27.0	740
7	Cancer Burden in the HIV-Infected Population in the United States. <i>Journal of the National Cancer Institute</i> , 2011, 103, 753-762.	6.3	698
8	The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 51-64.	329.8	516
9	Targeting of Low-Dose CT Screening According to the Risk of Lung-Cancer Death. <i>New England Journal of Medicine</i> , 2013, 369, 245-254.	27.0	492
10	Risk of Human Papillomavirus-Associated Cancers Among Persons With AIDS. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1120-1130.	6.3	468
11	HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. <i>Cancer</i> , 2008, 113, 3036-3046.	4.1	438
12	Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. <i>Blood</i> , 2006, 108, 3786-3791.	1.4	401
13	AIDS-Related Cancer and Severity of Immunosuppression in Persons With AIDS. <i>Journal of the National Cancer Institute</i> , 2007, 99, 962-972.	6.3	305
14	Second Cancers Among 104760 Survivors of Cervical Cancer: Evaluation of Long-Term Risk. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1634-1643.	6.3	303
15	Beyond Cervical Cancer: Burden of Other HPV-Related Cancers Among Men and Women. <i>Journal of Adolescent Health</i> , 2010, 46, S20-S26.	2.5	295
16	Increased Levels of Circulating Interleukin 6, Interleukin 8, C-Reactive Protein, and Risk of Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1112-1122.	6.3	273
17	Burden of potentially human papillomavirus-associated cancers of the oropharynx and oral cavity in the US, 1998-2003. <i>Cancer</i> , 2008, 113, 2901-2909.	4.1	264
18	Cigarette Smoking and Variations in Systemic Immune and Inflammation Markers. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	255

#	ARTICLE	IF	CITATIONS
19	Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. JAMA - Journal of the American Medical Association, 2016, 315, 2300.	7.4	248
20	Human Papillomavirus Infection with Multiple Types: Pattern of Coinfection and Risk of Cervical Disease. Journal of Infectious Diseases, 2011, 203, 910-920.	4.0	245
21	Human Papillomavirus and Diseases of the Upper Airway: Head and Neck Cancer and Respiratory Papillomatosis. Vaccine, 2012, 30, F34-F54.	3.8	228
22	Epidemiology and Clinical Aspects of HPV in Head and Neck Cancers. Head and Neck Pathology, 2012, 6, 16-24.	2.6	219
23	Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States. Journal of Clinical Oncology, 2018, 36, 262-267.	1.6	210
24	Circulating Inflammation Markers and Prospective Risk for Lung Cancer. Journal of the National Cancer Institute, 2013, 105, 1871-1880.	6.3	198
25	C-Reactive Protein and Risk of Lung Cancer. Journal of Clinical Oncology, 2010, 28, 2719-2726.	1.6	188
26	Eurogin Roadmap: Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. International Journal of Cancer, 2014, 134, 497-507.	5.1	164
27	Elevated risk of lung cancer among people with AIDS. Aids, 2007, 21, 207-213.	2.2	144
28	Chronic Obstructive Pulmonary Disease and Altered Risk of Lung Cancer in a Population-Based Case-Control Study. PLoS ONE, 2009, 4, e7380.	2.5	134
29	Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening. Annals of Internal Medicine, 2018, 169, 10.	3.9	130
30	Evolution of the Oropharynx Cancer Epidemic in the United States: Moderation of Increasing Incidence in Younger Individuals and Shift in the Burden to Older Individuals. Journal of Clinical Oncology, 2019, 37, 1538-1546.	1.6	127
31	Rising incidence of oral tongue cancer among white men and women in the United States, 1973-2012. Oral Oncology, 2017, 67, 146-152.	1.5	124
32	Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity. Journal of the American Dental Association, 2017, 148, 712-727.e10.	1.5	118
33	NHANES 2009-2012 Findings: Association of Sexual Behaviors with Higher Prevalence of Oral Oncogenic Human Papillomavirus Infections in U.S. Men. Cancer Research, 2015, 75, 2468-2477.	0.9	117
34	Impact of the HIV Epidemic on the Incidence Rates of Anal Cancer in the United States. Journal of the National Cancer Institute, 2012, 104, 1591-1598.	6.3	113
35	<i>Chlamydia pneumoniae</i> Infection and Risk for Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1498-1505.	2.5	98
36	Prevalence and Clustering Patterns of Human Papillomavirus Genotypes in Multiple Infections. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 2439-2445.	2.5	94

#	ARTICLE	IF	CITATIONS
37	Evaluation of Multiplexed Cytokine and Inflammation Marker Measurements: a Methodologic Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1902-1911.	2.5	89
38	Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1047-1054.	6.3	88
39	Pulmonary Infections and Risk of Lung Cancer Among Persons With AIDS. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 375-379.	2.1	85
40	Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. <i>Gynecologic Oncology</i> , 2014, 135, 297-304.	1.4	83
41	Assessment of Human Papillomavirus in Lung Tumor Tissue. <i>Journal of the National Cancer Institute</i> , 2011, 103, 501-507.	6.3	80
42	Body Mass Index, Physical Activity, and Serum Markers of Inflammation, Immunity, and Insulin Resistance. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2840-2849.	2.5	79
43	Circulating Inflammation Markers, Risk of Lung Cancer, and Utility for Risk Stratification. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	77
44	Using Prediction Models to Reduce Persistent Racial and Ethnic Disparities in the Draft 2020 USPSTF Lung Cancer Screening Guidelines. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1590-1594.	6.3	77
45	Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population. <i>Oral Oncology</i> , 2016, 60, 61-67.	1.5	75
46	Life-Gainedâ€“Based Versus Risk-Based Selection of Smokers for Lung Cancer Screening. <i>Annals of Internal Medicine</i> , 2019, 171, 623.	3.9	72
47	Association of Marijuana Smoking with Oropharyngeal and Oral Tongue Cancers: Pooled Analysis from the INHANCE Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 160-171.	2.5	67
48	A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma. <i>Blood</i> , 2013, 122, 951-957.	1.4	64
49	Second Cancers After Squamous Cell Carcinoma and Adenocarcinoma of the Cervix. <i>Journal of Clinical Oncology</i> , 2009, 27, 967-973.	1.6	59
50	Associations of Coffee Drinking with Systemic Immune and Inflammatory Markers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1052-1060.	2.5	59
51	Prevalence of Oral HPV Infection in Unvaccinated Men and Women in the United States, 2009-2016. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 977.	7.4	59
52	Markers of microbial translocation and risk of AIDS-related lymphoma. <i>Aids</i> , 2013, 27, 469-474.	2.2	58
53	Incidence of potentially human papillomavirusâ€“related neoplasms in the United States, 1978 to 2007. <i>Cancer</i> , 2013, 119, 2291-2299.	4.1	48
54	Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. <i>International Journal of Cancer</i> , 2017, 140, 600-610.	5.1	48

#	ARTICLE	IF	CITATIONS
55	Optimization of PCR based detection of human papillomavirus DNA from urine specimens. <i>Journal of Clinical Virology</i> , 2004, 29, 230-240.	3.1	47
56	A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1494-1503.	1.1	45
57	Underestimation of Relative Risks by Standardized Incidence Ratios for AIDS-Related Cancers. <i>Annals of Epidemiology</i> , 2008, 18, 230-234.	1.9	43
58	Detection of Human Papillomavirus DNA in Urine Specimens from Human Immunodeficiency Virus-Positive Women. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3155-3161.	3.9	42
59	Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer. <i>Carcinogenesis</i> , 2016, 37, 188-196.	2.8	41
60	Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods. <i>BMC Infectious Diseases</i> , 2015, 15, 544.	2.9	40
61	Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI. <i>Oral Oncology</i> , 2020, 108, 104736.	1.5	40
62	Prevalence of human papillomavirus genotypes in women from three clinical settings. <i>Journal of Medical Virology</i> , 2005, 75, 105-113.	5.0	39
63	HPV-associated Oropharyngeal Cancers—Are They Preventable?. <i>Cancer Prevention Research</i> , 2011, 4, 1346-1349.	1.5	37
64	High-Risk Oral Human Papillomavirus Load in the US Population, National Health and Nutrition Examination Survey 2009–2010. <i>Journal of Infectious Diseases</i> , 2014, 210, 441-447.	4.0	34
65	Leukoplakia, Oral Cavity Cancer Risk, and Cancer Survival in the U.S. Elderly. <i>Cancer Prevention Research</i> , 2015, 8, 857-863.	1.5	33
66	HPV and head and neck cancers: State-of-the-science. <i>Oral Oncology</i> , 2014, 50, 353-355.	1.5	32
67	Anthropometry and head and neck cancer: a pooled analysis of cohort data. <i>International Journal of Epidemiology</i> , 2015, 44, 673-681.	1.9	32
68	Differential Serum Cytokine Levels and Risk of Lung Cancer Between African and European Americans. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 488-497.	2.5	32
69	Circulating Markers of Interstitial Lung Disease and Subsequent Risk of Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2262-2272.	2.5	31
70	A prospective study of immune and inflammation markers and risk of lung cancer among female never smokers in Shanghai. <i>Carcinogenesis</i> , 2017, 38, 1004-1010.	2.8	31
71	Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. <i>Cancer</i> , 2012, 118, 5630-5636.	4.1	30
72	Human Papillomavirus-Specific Antibody Status in Oral Fluids Modestly Reflects Serum Status in Human Immunodeficiency Virus-Positive Individuals. <i>Vaccine Journal</i> , 2003, 10, 431-438.	3.1	27

#	ARTICLE	IF	CITATIONS
73	Tonsillectomy and Incidence of Oropharyngeal Cancers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 944-950.	2.5	25
74	Risk-Based Selection of Individuals for Oral Cancer Screening. <i>Journal of Clinical Oncology</i> , 2021, 39, 663-674.	1.6	24
75	Population Attributable Risks of Subtypes of Esophageal and Gastric Cancers in the United States. <i>American Journal of Gastroenterology</i> , 2021, 116, 1844-1852.	0.4	24
76	Risk of Gastrointestinal Cancers among Patients with Appendectomy: A Large-Scale Swedish Register-Based Cohort Study during 1970-2009. <i>PLoS ONE</i> , 2016, 11, e0151262.	2.5	24
77	A snapshot of the evolving epidemiology of oropharynx cancers. <i>Cancer</i> , 2018, 124, 2893-2896.	4.1	23
78	Invited Commentary: Circulating Inflammation Markers and Cancer Risk—Implications for Epidemiologic Studies. <i>American Journal of Epidemiology</i> , 2013, 177, 14-19.	3.4	22
79	Circulating TGF β 1 and VEGF and risk of cancer among liver transplant recipients. <i>Cancer Medicine</i> , 2015, 4, 1252-1257.	2.8	19
80	Development and validation of an individualized risk prediction model for oropharynx cancer in the US population. <i>Cancer</i> , 2019, 125, 4407-4416.	4.1	19
81	Distribution of human papillomavirus type 16 variants in human immunodeficiency virus type 1-positive and -negative women. <i>Journal of General Virology</i> , 2004, 85, 1237-1241.	2.9	18
82	A model for predicting clinical outcome in patients with human papillomavirus-positive tonsillar and base of tongue cancer. <i>European Journal of Cancer</i> , 2015, 51, 1580-1587.	2.8	18
83	Contemporary impact of tobacco use on periodontal disease in the USA. <i>Tobacco Control</i> , 2017, 26, 237-238.	3.2	16
84	Dental opinion leaders'™ perspectives on barriers and facilitators to HPV-related prevention. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1856-1862.	3.3	16
85	Lower Risk of Lung Cancer after Multiple Pneumonia Diagnoses. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 716-721.	2.5	15
86	Global burden of human papillomavirus-positive head and neck cancers. <i>Lancet Oncology</i> , The, 2014, 15, 1282-1283.	10.7	14
87	Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 825-832.	2.5	14
88	Circulating inflammation markers and colorectal adenoma risk. <i>Carcinogenesis</i> , 2019, 40, 765-770.	2.8	14
89	Risk of oral tongue cancer among immunocompromised transplant recipients and human immunodeficiency virus-infected individuals in the United States. <i>Cancer</i> , 2018, 124, 2515-2522.	4.1	12
90	Cancer risk in persons with HIV/AIDS in India: a review and future directions for research. <i>Infectious Agents and Cancer</i> , 2009, 4, 4.	2.6	11

#	ARTICLE	IF	CITATIONS
91	Management of Lung Cancer Screening Results Based on Individual Prediction of Current and Future Lung Cancer Risks. <i>Journal of Thoracic Oncology</i> , 2022, 17, 252-263.	1.1	11
92	Human papillomavirus genotypes among women with HIV: implications for research and prevention. <i>Aids</i> , 2006, 20, 2381-2383.	2.2	10
93	Hematologic and Biochemical Changes Associated with Human T Lymphotropic Virus Type 1 Infection in Jamaica: A Report from the Population-Based Blood Donors Study. <i>Clinical Infectious Diseases</i> , 2007, 45, 975-982.	5.8	8
94	Industrial hog farming is associated with altered circulating immunological markers. <i>Occupational and Environmental Medicine</i> , 2018, 75, 212-217.	2.8	8
95	Human Papillomavirus and Head and Neck Cancer. , 2010, , 87-116.		8
96	Contribution of Demographic and Behavioral Factors on the Changing Incidence Rates of Oropharyngeal and Oral Cavity Cancers in Northern California. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 978-984.	2.5	7
97	Associations between self-reported diabetes and 78 circulating markers of inflammation, immunity, and metabolism among adults in the United States. <i>PLoS ONE</i> , 2017, 12, e0182359.	2.5	7
98	Hematologic and Biochemical Changes Associated with Human T Lymphotropic Virus Type 1 Infection in Jamaica: A Report from the Population-Based Blood Donors Study. <i>Clinical Infectious Diseases</i> , 2007, 45, 975-982.	5.8	6
99	Tonsillectomy and Risk of Oropharyngeal Cancer: Implications for Research and Prevention. <i>Cancer Prevention Research</i> , 2015, 8, 577-579.	1.5	5
100	Using Immune Marker Panels to Evaluate the Role of Inflammation in Cancer: Summary of an NCI-Sponsored Workshop. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1427-1433.	2.5	4
101	Tumor-Based Case-Control Studies of Infection and Cancer: Muddling the When and Where of Molecular Epidemiology. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1959-1964.	2.5	3
102	Evaluating Discrimination of a Lung Cancer Risk Prediction Model Using Partial Risk-Score in a Two-Phase Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1196-1203.	2.5	3
103	Oral cavity anatomical site image classification and analysis. , 2022, 12037, .		3
104	Real-World HPV Vaccine Effectiveness Studies: Guideposts for Interpretation of Current and Future Studies. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1270-1271.	6.3	2
105	HPV16 E6 seropositivity and oropharyngeal cancer: Marker of exposure, risk, or disease?. <i>EBioMedicine</i> , 2021, 63, 103190.	6.1	2
106	Abstract PR-13: Potential effect on racial/ethnic disparities of removing racial/ethnic variables from risk models: The example of lung-cancer screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, PR-13-PR-13.	2.5	1
107	Reply to P.A. LeppÄluoto. <i>Journal of Clinical Oncology</i> , 2009, 27, 3066-3067.	1.6	0
108	O41-4Ä€...Altered circulating immune and inflammation markers among hog farmers in the study of biomarkers of exposure and effect in agriculture. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
109	Response to Brandt, Bednarz-Knoll, Kleinheinz et al. Journal of the National Cancer Institute, 2020, 112, 970-971.	6.3	0
110	Herd Protection Against Oral HPV Infectionâ€™Reply. JAMA - Journal of the American Medical Association, 2020, 323, 478.	7.4	0